Status:
COMPLETED
Clinical Effects of Oral Trehalose In Patients With Spinocerebellar Ataxia 3
Lead Sponsor:
National University of Malaysia
Conditions:
Spinocerebellar Ataxia 3
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
There are no clinically established treatments which have been proven to delay the disease progression in spinocerebellar ataxia (SCA) 3. Most available treatments are only for symptom alleviation, an...
Detailed Description
This prospective single arm interventional study involved 13 genetically confirmed spinocerebellar ataxia (SCA) 3 patients with no concomitant diabetes, over 6 months. Following baseline assessment, p...
Eligibility Criteria
Inclusion
- DNA diagnosis of SCA 3 in the study subject of his/ her affected family member(s)
- Consent to participate in the study
- The age of 18 years and older
Exclusion
- Unconfirmed SCA 3
- Concomitant disorder(s) that affect SARA and other ataxia measures used in this study
- Diabetes
- Malabsorption of trehalose underlies intolerance to mushrooms, since the lack of absorption results in diarrhoea and intestinal distress.
- Less than 18 years old
Key Trial Info
Start Date :
March 7 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 7 2018
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT04426149
Start Date
March 7 2018
End Date
September 7 2018
Last Update
June 11 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pusat Perubatan Universiti Kebangsaan Malaysia
Kuala Lumpur, Malaysia, 56000